Fig. 2
From: A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies
DEPTAC facilitates tau dephosphorylation and degradation in primary neurons with hTau-overexpression. a–d DEPTAC promoted tau dephosphorylation at the AD-related pS199, pT205, pS396, pS404, and AT8 epitope with reduced total tau probed by Tau5 antibody, in a dose- and time-dependent manner in cultured primary rat neurons with lentivirus-mediated hTau-overexpression (a, c). Data were normalized to the level of β-actin. One-way ANOVA followed by Tukey’s multiple comparisons tests, *p < 0.01 compared with baseline, n = 3 cell wells for each group. By immunofluorescence staining, DEPTAC (200 μM for 24 h) also reduced the averaged immunoreactive (IR) intensity of phospho-tau (b, d). Scale bar, 50 μm. Two-way ANOVA followed by Tukey’s multiple comparisons tests. *p < 0.05, **p < 0.01, n = 3 cell wells in each group. e, f DEPTAC promoted tau dephosphorylation with reduced efficiency in the presence of MG132. Two-way ANOVA followed by Tukey’s multiple comparisons tests, *p < 0.05, n = 3 cell wells in each group
